Key clinical point: Neoadjuvant immunotherapy may improve surgical outcomes for patients with early non–small cell lung cancer.
Major finding: Overall, major pathological response rates were 17% with nivolumab monotherapy and 33% with nivolumab/ipilimumab.
Study details: Phase 2 randomized trial in 44 patients with stage I-IIIA NSCLC.
Disclosures: The study was supported by Bristol-Myers Squibb. Dr. Cascone disclosed honoraria from the company. Dr. Diehn reported stock ownership in, consulting for, research funding from, and travel expenses from various companies.
Cascone T et al. ASCO 2019, Abstract 8504.